Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy

Cancer is a disease that induces many local and systemic changes in immunity. The difficult nature of ovarian cancer stems from the lack of characteristic symptoms that contributes to a delayed diagnosis and treatment. Despite the enormous progress in immunotherapy, its efficacy remains limited. The...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 1018256
Main Authors Rajtak, Alicja, Ostrowska-Leśko, Marta, Żak, Klaudia, Tarkowski, Rafał, Kotarski, Jan, Okła, Karolina
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.11.2022
Subjects
biomarkers
Carcinoma, Ovarian Epithelial
Female
heterogeneity
Humans
immune cells
Immunologic Factors
Immunology
Immunotherapy
ovarian cancer
Ovarian Neoplasms - therapy
Tumor Microenvironment
ovarian cancer
biomarkers
immunotherapy
multi-omics
immune cells
tumor microenvironment
TME
heterogeneity
Online AccessGet full text

Cover

More Information
Summary:Cancer is a disease that induces many local and systemic changes in immunity. The difficult nature of ovarian cancer stems from the lack of characteristic symptoms that contributes to a delayed diagnosis and treatment. Despite the enormous progress in immunotherapy, its efficacy remains limited. The heterogeneity of tumors, lack of diagnostic biomarkers, and complex immune landscape are the main challenges in the treatment of ovarian cancer. Integrative approaches that combine the tumor microenvironment - local immunity - together with periphery - systemic immunity - are urgently needed to improve the understanding of the disease and the efficacy of treatment. In fact, multiparametric analyses are poised to improve our understanding of ovarian tumor immunology. We outline an integrative approach including local and systemic immunity in ovarian cancer. Understanding the nature of both localized and systemic immune responses will be crucial to boosting the efficacy of immunotherapies in ovarian cancer patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Hiroshi Kagamu, Saitama Medical University International Medical Center, Japan; Hou Yuzhu, Xi’an Jiaotong University, China; Cecile Gouttefangeas, University of Tübingen, Germany
Edited by: Xiao Liang, Sichuan University, China
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.1018256